All OpenAI’s Models and Initiatives in Research & Medical Sciences So Far (2024-2026)

Key Takeaways

• OpenAI has built a full healthcare ecosystem since 2024, spanning clinical care, research, drug discovery, and biodefense, far beyond answering medical questions.
• GPT-Rosalind is the centerpiece, a model built for life sciences research, backed by Amgen, Moderna, Novo Nordisk, and Thermo Fisher.
• The company is also defining how medical AI gets measured, through benchmarks like HealthBench, HealthBench Professional, and LifeSciBench.
• Consumer and enterprise products now anchor the push, with ChatGPT Health alone drawing around 230 million weekly health users.

Over the past few years, OpenAI’s ambitions in healthcare have grown well beyond just answering medical questions. The company has been building a powerful ecosystem that reaches all corners of the field such as clinical care, biomedical research, drug discovery, public health, and the infrastructure driving life sciences. It all started with simple healthcare evaluations and clinical assistant tools, but things have moved beyond that, fast. Now you see purpose built health products, scientific benchmarks, biotech partnerships, and even specialized AI models created for biological reasoning.

OpenAI is not merely positioning its models as tools that can assist scientists and clinicians. It is creating purpose built systems, benchmarks, and partnerships aimed at integrating AI directly into healthcare delivery, medical research, pharmaceutical development, and biological threat preparedness. The company is working side by side with hospitals, health tech companies, biotech firms, and public health organizations.

Table of Contents

1. LifeSciBench (17 June 2026)

OpenAI rolled out LifeSciBench, a benchmark pushing AI to actually do life science work, going way beyond just answering biology questions. This benchmark includes 750 tasks stretching across real scientific workflows like evidence analysis, experimental design, treatment optimization, validating results, and scientific communication. The whole thing is massive: built with input from 173 scientists, 453 expert reviewers, over a thousand files, and more than 19,000 grading criteria.

OpenAI’s message here is clear: they think scientific AI should be measured by what it can do with real world research, not just how it handles some academic exam questions. GPT-Rosalind achieved the highest reported performance on the LifeSciBench benchmark, but there is still a long way to go, especially in experimental design and handling numbers.

2. Biodefense in the Intelligence Age (4 June 2026)

With their biodefense initiative, OpenAI moved the conversation out of the lab into questions of global health and resilience. The project looked at how advanced AI can help public health agencies, governments, and scientific teams on everything from disease tracking and preparedness to diagnostics and emergency response. The company treated its technology not as a gadget, but as building blocks for national and global health security.

3. GPT-Rosalind (16 April 2026)

The centerpiece of OpenAI’s scientific efforts is GPT-Rosalind, introduced in April 2026 as a specialized model for life sciences research. Unlike general purpose models such as GPT-4o or GPT-5, Rosalind was specifically designed for biological reasoning, scientific evidence evaluation, genomics, protein engineering, drug discovery, and translational medicine.  

The company claims Rosalind can reason across molecules, proteins, genes, pathways, disease biology, literature, databases, and even lab workflows. It does not just answer questions, it can blend evidence from different sources, help spot new drug targets, analyze biological data, and support new research ideas.

Beyond the model itself, OpenAI has built a whole ecosystem around Rosalind by integrating it with Codex, scientific data banks, and custom research tools. Researchers can take big scientific questions and turn them into repeatable workflows.

Several major life sciences organizations are already involved, including Amgen, Moderna, Novo Nordisk, Thermo Fisher Scientific, and Oracle Health and Life Sciences. These partnerships signal OpenAI’s intention to become a core technology provider for biotechnology and pharmaceutical research. Rosalind also extends its reach into public health with the Rosalind Biodefense Program, reinforcing the company’s increasing commitment to defensive uses in biology.

4. HealthBench Professional (30 April 2026)

Unlike the old standard medical tests, HealthBench Professional grades AI systems on the actual tasks clinicians do: care consulting, documenting and writing, and medical research.

This benchmark draws from over 15,000 clinician patient interactions, with tougher cases nearly 3.5 times more often. Plus, a third of the challenges come from adversarial testing where physicians tried to trip up the AI, putting it through its paces in real clinical terms. The company is focusing its evaluation work to match the real demands of healthcare practice, not just academic tests.

5. ChatGPT Health (7 January 2026)

In early 2026, OpenAI rolled out ChatGPT Health, a platform built just for healthcare, pulling together medical questions, records, and patient guidance all in one place. At launch, the company said around 230 million users every week bring their health questions to ChatGPT.

This marks the company’s first move into a large scale, purpose driven health platform, going above and beyond just slipping health features into their general chatbot. It proves that healthcare now stands as one of the biggest, most valuable uses for generative AI.

6. OpenAI for Healthcare (8 January 2026)

OpenAI for Healthcare is a platform built for big organizations such as hospitals, health systems, administrators, researchers, and clinical teams. Here, the company offers specialized AI capabilities, tech governance, robust security, and compliance features tailored for the medical world. It positions OpenAI in healthcare infrastructure as a provider than just a mere model developer.

7. Healthify (2 December 2025)

Healthify is OpenAI’s shot at bringing AI powered healthcare directly to consumers. Most of the company’s healthcare projects are aimed at professionals, but Healthify helps people figure out health information, get wellness guidance, and handle routine healthcare tasks. It is a big move in OpenAI’s plan to combine medical knowledge, health records, and tailored assistance in products that help people make real world health decisions.

8. Retro Biosciences (22 August 2025)

OpenAI collaborated with Retro Biosciences to expand its reach into longevity research and biotechnology. The partnership is about speeding up life sciences research with advanced AI. With Retro working on making healthy human lives longer, this early alliance showed the company’s deepening interest in big breakthroughs in biotech and biomedical discovery.

9. Clinical Copilot (22 July 2025)

One of OpenAI’s major healthcare deployments came through Penda Health. Together, they created an AI Clinical Copilot which is a tool that helps doctors during real patient visits. The company says this system cut diagnostic errors by 16%, turning AI into a real time assistant in the exam room, not just a background information resource. This collaboration was one of OpenAI’s first signals that their vision is to support clinicians, making them better, not replace them.

10. HealthBench (12 May 2025)

Back in May 2025, OpenAI set the standard with HealthBench, a huge project to measure how well and how safely AI systems perform in healthcare. It is one of the most ambitious healthcare AI evaluation efforts ever.

HealthBench was built with 262 physicians from 60 countries, covering 49 languages and 26 specialties. It includes nearly 49,000 detailed scoring criteria written by physicians for response evaluation. OpenAI reported that model performance improved substantially over time. HealthBench became the foundation for later frameworks like HealthBench Professional and new clinical benchmarks.

11. Color Health (17 June 2024)

OpenAI’s work with Color Health focused on using AI for cancer care and direct patient support. This partnership aimed to give patients better access to healthcare information, navigate treatment plans, and assist clinical workflows. For the company, it was an early, highly visible example of working with a healthcare company focused directly on improving patient outcomes.

12. Thrive AI Health (8 July 2024)

In 2024, OpenAI’s Startup Fund joined with Arianna Huffington’s Thrive Global to launch Thrive AI Health. The idea was to build a hyper personalized AI health coach to guide users in improving sleep, nutrition, fitness, stress management, and general wellness. Unlike projects aimed at hospitals or clinics, Thrive AI Health targets prevention, helping users shape healthy behaviors before medical problems even show up. This was a clear sign that the company believes AI can make a positive impact on health long before the need for people to visit a clinic.

13. Building an Early Warning System for LLM-Aided Biological Threat Creation (31 January 2024)

As OpenAI’s AI systems became more sophisticated in biology, the risks of misuse only increased.  In response, the company launched research focused on detecting and mitigating biological threats that could potentially be assisted by advanced AI systems. The project explored whether AI could spot dangerous biological activity early and help build safeguards as these models grow more powerful.

Also read: OpenAI’s LifeSciBench Evaluates AI for Scientific Purposes 

Wrapping Up

From 2024 to 2026, OpenAI’s medical AI and healthcare strategies vary from a collection of experiments to a coordinated push across clinical medicine, research, biotech, public health, and even drug discovery. The evolution is clear: they started with collaborations like Thrive AI Health and Retro Biosciences, moved into huge evaluation projects like HealthBench, ran clinical pilots like Penda Health’s Clinical Copilot, launched dedicated products like ChatGPT Health, and eventually created GPT-Rosalind, a model built from scratch for life sciences.